Bill Text: FL H0873 | 2010 | Regular Session | Introduced
Bill Title: Controlled Substances
Spectrum: Partisan Bill (Republican 1-0)
Status: (Failed) 2010-04-30 - Died in Committee on Health Care Regulation Policy (HFPC) [H0873 Detail]
Download: Florida-2010-H0873-Introduced.html
HB 873 |
1 | |
2 | An act relating to controlled substances; amending s. |
3 | 893.03, F.S.; revising the list of controlled substances |
4 | in Schedules I, II, III, IV, and V; providing that the |
5 | salts, isomers, or salts of isomers are included within |
6 | certain substances listed in Schedule III; providing an |
7 | effective date. |
8 | |
9 | Be It Enacted by the Legislature of the State of Florida: |
10 | |
11 | Section 1. Paragraph (c) of subsection (1), paragraphs (a) |
12 | and (b) of subsection (2), paragraph (a) of subsection (3), |
13 | subsection (4), and paragraph (b) of subsection (5) of section |
14 | 893.03, Florida Statutes, are amended to read: |
15 | 893.03 Standards and schedules.-The substances enumerated |
16 | in this section are controlled by this chapter. The controlled |
17 | substances listed or to be listed in Schedules I, II, III, IV, |
18 | and V are included by whatever official, common, usual, |
19 | chemical, or trade name designated. The provisions of this |
20 | section shall not be construed to include within any of the |
21 | schedules contained in this section any excluded drugs listed |
22 | within the purview of 21 C.F.R. s. 1308.22, styled "Excluded |
23 | Substances"; 21 C.F.R. s. 1308.24, styled "Exempt Chemical |
24 | Preparations"; 21 C.F.R. s. 1308.32, styled "Exempted |
25 | Prescription Products"; or 21 C.F.R. s. 1308.34, styled "Exempt |
26 | Anabolic Steroid Products." |
27 | (1) SCHEDULE I.-A substance in Schedule I has a high |
28 | potential for abuse and has no currently accepted medical use in |
29 | treatment in the United States and in its use under medical |
30 | supervision does not meet accepted safety standards. The |
31 | following substances are controlled in Schedule I: |
32 | (c) Unless specifically excepted or unless listed in |
33 | another schedule, any material, compound, mixture, or |
34 | preparation which contains any quantity of the following |
35 | hallucinogenic substances or which contains any of their salts, |
36 | isomers, and salts of isomers, whenever the existence of such |
37 | salts, isomers, and salts of isomers is possible within the |
38 | specific chemical designation: |
39 | 1. Alpha-ethyltryptamine. |
40 | 2. 2-Amino-4-methyl-5-phenyl-2-oxazoline (4- |
41 | methylaminorex). |
42 | 3. 2-Amino-5-phenyl-2-oxazoline (Aminorex). |
43 | 4. 4-Bromo-2,5-dimethoxyamphetamine. |
44 | 5. 4-Bromo-2, 5-dimethoxyphenethylamine. |
45 | 6. Bufotenine. |
46 | 7. Cannabis. |
47 | 8. Cathinone. |
48 | 9. Diethyltryptamine. |
49 | 10. 2,5-Dimethoxyamphetamine. |
50 | 11. 2,5-Dimethoxy-4-ethylamphetamine (DOET). |
51 | 12. Dimethyltryptamine. |
52 | 13. N-Ethyl-1-phenylcyclohexylamine (PCE) (Ethylamine |
53 | analog of phencyclidine). |
54 | 14. N-Ethyl-3-piperidyl benzilate. |
55 | 15. N-ethylamphetamine. |
56 | 16. Fenethylline. |
57 | 17. N-Hydroxy-3,4-methylenedioxyamphetamine. |
58 | 18. Ibogaine. |
59 | 19. Lysergic acid diethylamide (LSD). |
60 | 20. Mescaline. |
61 | 21. Methcathinone. |
62 | 22. 5-Methoxy-3,4-methylenedioxyamphetamine. |
63 | 23. 4-methoxyamphetamine. |
64 | 24. 4-methoxymethamphetamine. |
65 | 25. 4-Methyl-2,5-dimethoxyamphetamine. |
66 | 26. 3,4-Methylenedioxy-N-ethylamphetamine. |
67 | 27. 3,4-Methylenedioxyamphetamine. |
68 | 28. N-Methyl-3-piperidyl benzilate. |
69 | 29. N,N-dimethylamphetamine. |
70 | 30. Parahexyl. |
71 | 31. Peyote. |
72 | 32. N-(1-Phenylcyclohexyl)-pyrrolidine (PCPY) (Pyrrolidine |
73 | analog of phencyclidine). |
74 | 33. Psilocybin. |
75 | 34. Psilocyn. |
76 | 35. Salvia divinorum, except for any drug product approved |
77 | by the United States Food and Drug Administration which contains |
78 | Salvia divinorum or its isomers, esters, ethers, salts, and |
79 | salts of isomers, esters, and ethers, whenever the existence of |
80 | such isomers, esters, ethers, and salts is possible within the |
81 | specific chemical designation. |
82 | 36. Salvinorin A, except for any drug product approved by |
83 | the United States Food and Drug Administration which contains |
84 | Salvinorin A or its isomers, esters, ethers, salts, and salts of |
85 | isomers, esters, and ethers, whenever the existence of such |
86 | isomers, esters, ethers, and salts is possible within the |
87 | specific chemical designation. |
88 | 37. Tetrahydrocannabinols. |
89 | 38. 1-[1-(2-Thienyl)-cyclohexyl]-piperidine (TCP) |
90 | (Thiophene analog of phencyclidine). |
91 | 39. 3,4,5-Trimethoxyamphetamine. |
92 | 40. Alpha-methyltryptamine. |
93 | 41. 1-(1-Phenylcyclohexyl) pyrrolidine. |
94 | 42. 2,5-Dimethoxy-4-(n)-propylthiophenethylamine. |
95 | 43. 5-Methoxy-N, N-diisopropyltryptamine. |
96 | 44. N-Benzylpiperazine. |
97 | (2) SCHEDULE II.-A substance in Schedule II has a high |
98 | potential for abuse and has a currently accepted but severely |
99 | restricted medical use in treatment in the United States, and |
100 | abuse of the substance may lead to severe psychological or |
101 | physical dependence. The following substances are controlled in |
102 | Schedule II: |
103 | (a) Unless specifically excepted or unless listed in |
104 | another schedule, any of the following substances, whether |
105 | produced directly or indirectly by extraction from substances of |
106 | vegetable origin or independently by means of chemical |
107 | synthesis: |
108 | 1. Opium and any salt, compound, derivative, or |
109 | preparation of opium, except nalmefene or isoquinoline alkaloids |
110 | of opium, including, but not limited to the following: |
111 | a. Raw opium. |
112 | b. Opium extracts. |
113 | c. Opium fluid extracts. |
114 | d. Powdered opium. |
115 | e. Granulated opium. |
116 | f. Tincture of opium. |
117 | g. Codeine. |
118 | h. Ethylmorphine. |
119 | i. Etorphine hydrochloride. |
120 | j. Hydrocodone. |
121 | k. Hydromorphone. |
122 | l. Levo-alphacetylmethadol (also known as levo-alpha- |
123 | acetylmethadol, levomethadyl acetate, or LAAM). |
124 | m. Metopon (methyldihydromorphinone). |
125 | n. Morphine. |
126 | o. Oxycodone. |
127 | p. Oxymorphone. |
128 | q. Thebaine. |
129 | r. Dihydroetorphine. |
130 | 2. Any salt, compound, derivative, or preparation of a |
131 | substance which is chemically equivalent to or identical with |
132 | any of the substances referred to in subparagraph 1., except |
133 | that these substances shall not include the isoquinoline |
134 | alkaloids of opium. |
135 | 3. Any part of the plant of the species Papaver |
136 | somniferum, L. |
137 | 4. Cocaine or ecgonine, including any of their |
138 | stereoisomers, and any salt, compound, derivative, or |
139 | preparation of cocaine or ecgonine. |
140 | (b) Unless specifically excepted or unless listed in |
141 | another schedule, any of the following substances, including |
142 | their isomers, esters, ethers, salts, and salts of isomers, |
143 | esters, and ethers, whenever the existence of such isomers, |
144 | esters, ethers, and salts is possible within the specific |
145 | chemical designation: |
146 | 1. Alfentanil. |
147 | 2. Alphaprodine. |
148 | 3. Anileridine. |
149 | 4. Bezitramide. |
150 | 5. Bulk propoxyphene (nondosage forms). |
151 | 6. Carfentanil. |
152 | 7. Dihydrocodeine. |
153 | 8. Diphenoxylate. |
154 | 9. Fentanyl. |
155 | 10. Isomethadone. |
156 | 11. Levomethorphan. |
157 | 12. Levorphanol. |
158 | 13. Metazocine. |
159 | 14. Methadone. |
160 | 15. Methadone-Intermediate,4-cyano-2- |
161 | dimethylamino-4,4-diphenylbutane. |
162 | 16. Moramide-Intermediate,2-methyl- |
163 | 3-morpholoino-1,1-diphenylpropane-carboxylic acid. |
164 | 17. Nabilone. |
165 | 18. Pethidine (meperidine). |
166 | 19. Pethidine-Intermediate-A,4-cyano-1- |
167 | methyl-4-phenylpiperidine. |
168 | 20. Pethidine-Intermediate-B,ethyl-4- |
169 | phenylpiperidine-4-carboxylate. |
170 | 21. Pethidine-Intermediate-C,1-methyl-4- phenylpiperidine- |
171 | 4-carboxylic acid. |
172 | 22. Phenazocine. |
173 | 23. Phencyclidine. |
174 | 24. 1-Phenylcyclohexylamine. |
175 | 25. Piminodine. |
176 | 26. 1-Piperidinocyclohexanecarbonitrile. |
177 | 27. Racemethorphan. |
178 | 28. Racemorphan. |
179 | 29. Sufentanil. |
180 | 30. Lisdexamfetamine. |
181 | 31. Remifentanil. |
182 | (3) SCHEDULE III.-A substance in Schedule III has a |
183 | potential for abuse less than the substances contained in |
184 | Schedules I and II and has a currently accepted medical use in |
185 | treatment in the United States, and abuse of the substance may |
186 | lead to moderate or low physical dependence or high |
187 | psychological dependence or, in the case of anabolic steroids, |
188 | may lead to physical damage. The following substances are |
189 | controlled in Schedule III: |
190 | (a) Unless specifically excepted or unless listed in |
191 | another schedule, any material, compound, mixture, or |
192 | preparation which contains any quantity of the following |
193 | substances having a depressant or stimulant effect on the |
194 | nervous system, including its salts, isomers, and salts of |
195 | isomers whenever the existence of such salts, isomers, or salts |
196 | of isomers is possible within the specific chemical designation: |
197 | 1. Any substance which contains any quantity of a |
198 | derivative of barbituric acid, including thiobarbituric acid, or |
199 | any salt of a derivative of barbituric acid or thiobarbituric |
200 | acid, including, but not limited to, butabarbital and |
201 | butalbital. |
202 | 2. Benzphetamine. |
203 | 3. Chlorhexadol. |
204 | 4. Chlorphentermine. |
205 | 5. Clortermine. |
206 | 6. Lysergic acid. |
207 | 7. Lysergic acid amide. |
208 | 8. Methyprylon. |
209 | 9. Phendimetrazine. |
210 | 10. Sulfondiethylmethane. |
211 | 11. Sulfonethylmethane. |
212 | 12. Sulfonmethane. |
213 | 13. Tiletamine and zolazepam |
214 | 14. Embutramide. |
215 | (4) SCHEDULE IV.-A substance in Schedule IV has a low |
216 | potential for abuse relative to the substances in Schedule III |
217 | and has a currently accepted medical use in treatment in the |
218 | United States, and abuse of the substance may lead to limited |
219 | physical or psychological dependence relative to the substances |
220 | in Schedule III. Unless specifically excepted or unless listed |
221 | in another schedule, any material, compound, mixture, or |
222 | preparation which contains any quantity of the following |
223 | substances, including its salts, isomers, and salts of isomers |
224 | whenever the existence of such salts, isomers, and salts of |
225 | isomers is possible within the specific chemical designation, |
226 | are controlled in Schedule IV: |
227 | (a) Alprazolam. |
228 | (b) Barbital. |
229 | (c) Bromazepam. |
230 | (d) Camazepam. |
231 | (e) Cathine. |
232 | (f) Chloral betaine. |
233 | (g) Chloral hydrate. |
234 | (h) Chlordiazepoxide. |
235 | (i) Clobazam. |
236 | (j) Clonazepam. |
237 | (k) Clorazepate. |
238 | (l) Clotiazepam. |
239 | (m) Cloxazolam. |
240 | (n) Delorazepam. |
241 | (o) Propoxyphene (dosage forms). |
242 | (p) Diazepam. |
243 | (q) Diethylpropion. |
244 | (r) Estazolam. |
245 | (s) Ethchlorvynol. |
246 | (t) Ethinamate. |
247 | (u) Ethyl loflazepate. |
248 | (v) Fencamfamin. |
249 | (w) Fenfluramine. |
250 | (x) Fenproporex. |
251 | (y) Fludiazepam. |
252 | (z) Flurazepam. |
253 | (aa) Halazepam. |
254 | (bb) Haloxazolam. |
255 | (cc) Ketazolam. |
256 | (dd) Loprazolam. |
257 | (ee) Lorazepam. |
258 | (ff) Lormetazepam. |
259 | (gg) Mazindol. |
260 | (hh) Mebutamate. |
261 | (ii) Medazepam. |
262 | (jj) Mefenorex. |
263 | (kk) Meprobamate. |
264 | (ll) Methohexital. |
265 | (mm) Methylphenobarbital. |
266 | (nn) Midazolam. |
267 | (oo) Nimetazepam. |
268 | (pp) Nitrazepam. |
269 | (qq) Nordiazepam. |
270 | (rr) Oxazepam. |
271 | (ss) Oxazolam. |
272 | (tt) Paraldehyde. |
273 | (uu) Pemoline. |
274 | (vv) Pentazocine. |
275 | (ww) Phenobarbital. |
276 | (xx) Phentermine. |
277 | (yy) Pinazepam. |
278 | (zz) Pipradrol. |
279 | (aaa) Prazepam. |
280 | (bbb) Propylhexedrine, excluding any patent or proprietary |
281 | preparation containing propylhexedrine, unless otherwise |
282 | provided by federal law. |
283 | (ccc) Quazepam. |
284 | (ddd) Tetrazepam. |
285 | (eee) SPA[(-)-1 dimethylamino-1, 2 diphenylethane]. |
286 | (fff) Temazepam. |
287 | (ggg) Triazolam. |
288 | (hhh) Not more than 1 milligram of difenoxin and not less |
289 | than 25 micrograms of atropine sulfate per dosage unit. |
290 | (iii) Butorphanol tartrate. |
291 | (jjj) Carisoprodol. |
292 | (kkk) Zopiclone. |
293 | (lll) Zaleplon. |
294 | (mmm) Zolpidem. |
295 | (nnn) Modafinil. |
296 | (ooo) Petrichloral. |
297 | (ppp) Sibutramine. |
298 | (qqq) Dichloralphenazone. |
299 | (5) SCHEDULE V.-A substance, compound, mixture, or |
300 | preparation of a substance in Schedule V has a low potential for |
301 | abuse relative to the substances in Schedule IV and has a |
302 | currently accepted medical use in treatment in the United |
303 | States, and abuse of such compound, mixture, or preparation may |
304 | lead to limited physical or psychological dependence relative to |
305 | the substances in Schedule IV. |
306 | (b) Narcotic drugs. Unless specifically excepted or unless |
307 | listed in another schedule, any material, compound, mixture, or |
308 | preparation containing any of the following narcotic drugs and |
309 | their salts: |
310 | 1. Buprenorphine. |
311 | 2. Pregabalin. |
312 | 3. Not more than 0.5 milligrams of difenoxin and not less |
313 | than 25 micrograms of atrophine sulfate per dosage unit. |
314 | Section 2. This act shall take effect July 1, 2010. |
CODING: Words |